Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
- 539 Downloads
Weight gain is a common side effect of many widely used drugs. Weight gain of a few kilograms to an increase of 10% or more of initial body weight has been described. Not only the weight gain as such puts a burden on the health risks of the involved patients, the accompanying increase in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and cardiovascular risk factors urges the caregiver to identify and to closely monitor the patients at risk. In this review, the different classes of drugs with significant weight gaining properties and the metabolic consequences are described. Specific attention is given to pathogenetic mechanisms underlying the metabolic effects and to potential therapeutic measures to prevent them.
KeywordsDrug-induced obesity Mechanisms Metabolic syndrome Antipsychotics Therapy
Compliance with ethical standards
Conflict of interest
Luc Van Gaal has received honoraria as speaker, consultant, and member of the international Advisory Board of Novo Nordisk, Eli-Lilly, Astra Zeneca, Janssen J&J, Merck MSD, Boehringer Ingelheim, Servier, and Sanofi. Ann Verhaegen has received honoraria as a speaker and member of the national Advisory Board of Eli-Lilly, Boehringer Ingelheim, Novo Nordisk, Amgen, Janssen J&J, Merck MSD, Astra Zeneca, and Sanofi.
This article does not contain any studies with human participants or animals performed by any of the authors.
Since this is a review, informed consent is not applicable.
The authors did not receive funding for this manuscript or for research in this field.
- 24.Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 21(1):8–24CrossRefGoogle Scholar
- 48.Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. Clin Psych 62(suppl 7):4–10Google Scholar
- 69.Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR (2010) Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled trials. J Clin Psychopharmacol 30(6):656–660CrossRefPubMedGoogle Scholar
- 85.Gierisch JM, Nieuwsma JA, Bradford DW et al (2013) Interventions to improve cardiovascular risk factors in people with serious mental illness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Report No.: 13-EHC063-EF. AHRQ Comparative Effectiveness ReviewsGoogle Scholar
- 90.Mukundan A, Faulkner G, Cohn T, Remington G (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev (12):CD006629. doi: 10.1002/14651858.CD006629.pub2
- 97.Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2017.1220 PubMedGoogle Scholar